Tigermet is a Chinese company that helps other companies make medicine. They are not doing as well because fewer people need their help right now. But they are lucky because they don't have to worry about some rules in the US that could hurt other similar companies. Also, China is trying to help this kind of business by making new policies. Tigermet's price is still high compared to how much money they make. Read from source...

1. Inconsistency in Tigermed's strategy and performance: The article claims that Tigermed has been scaling back its clinical programs amid falling demand for drugs research, but also states that the company is less exposed to U.S. policy risks than WuXi AppTec. This implies that Tigermed is reducing its clinical programs due to external factors, rather than focusing on its core strengths and opportunities in China's domestic market.
2. Bias towards WuXi AppTec as a prime example of Chinese biopharma companies: The article repeatedly mentions WuXi AppTec as a contrast to Tigermed, without providing any evidence or analysis of how WuXi AppTec is performing better or worse than Tigermet in terms of revenue growth, profitability, innovation, or market share. This creates an unfair comparison and undermines the credibility of Tigermed's performance and prospects.
3. Emotional language and exaggerated claims: The article uses phrases such as "China’s chilly biopharma sector", "fears of a U.S. crackdown on Chinese biotech companies", and "a move that could spell disaster for Chinese medical contracting companies". These words convey a negative tone and imply a sense of urgency and AIger, without providing any factual support or data to back up these claims.
4. Overemphasis on U.S. policy risks: The article devotes more space and attention to the potential impact of U.S. policies on Chinese biopharma companies, rather than focusing on the domestic opportunities and challenges that Tigermed faces in China's growing biomedical industry. This creates a one-sided and incomplete picture of Tigermed's situation and outlook.
5. Lack of analysis and evidence for the claim that Beijing and Guangzhou policies could stimulate investment in the sector: The article mentions these policies as a positive factor for Tigermed, but does not provide any details or examples of how these policies are designed, implemented, or beneficial to Tigermed's business model, research pipeline, or competitive edge. This leaves readers with an uninformed and vague impression of the potential impact of these policies on Tigermed's performance and prospects.